Get the Stockscreener App
6.34
1.55%
-0.10
Immucell Corp stock is traded at $6.34, with a volume of 251.
It is down -1.55% in the last 24 hours and down -3.21% over the past month.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
See More
Previous Close:
$6.44
Open:
$6.34
24h Volume:
251
Relative Volume:
0.01
Market Cap:
$57.35M
Revenue:
$27.64M
Net Income/Loss:
$-1.04M
P/E Ratio:
-55.76
EPS:
-0.1137
Net Cash Flow:
$2.48M
1W Performance:
+3.09%
1M Performance:
-3.21%
6M Performance:
+5.14%
1Y Performance:
+32.64%
1-Day Range:
$6.34
$6.34
1-Week Range:
$6.00
$6.45
52-Week Range:
$4.52
$7.60
Immucell Corp Stock (ICCC) Company Profile
Name
Immucell Corp
Sector
Industry
Phone
(207) 878-2770
Address
56 EVERGREEN DR, PORTLAND, ME
Compare ICCC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCC
Immucell Corp
|
6.34 | 58.26M | 27.64M | -1.04M | 2.48M | -0.1137 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Immucell Corp Stock (ICCC) Latest News
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
ImmuCell (ICCC) director exercises 25,000 options and ends with 205,700 shares - Stock Titan
ImmuCell (ICCC) CEO granted 109,500 stock options with strict profit hurdle - Stock Titan
ICCC Earnings History & Surprises | EPS & Revenue Results | IMMUCELL CORP (NASDAQ:ICCC) - ChartMill
ImmuCell Corporation Files Form 8-K with SEC Detailing Corporate Information and Press Release March 2026 - Minichart
ImmuCell appoints Kathy Turner to board of directors - Investing.com
ImmuCell (NASDAQ: ICCC) names Kathy Turner to Board as Rosgen retires - Stock Titan
Former Elanco director joins ImmuCell board in calf-health push - Stock Titan
ImmuCell appoints former Elanco board member Kathy Turner to board - Investing.com
ICCC SEC FilingsImmucell 10-K, 10-Q, 8-K Forms - Stock Titan
ImmuCell Corp (ICCC) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges By GuruFocus - Investing.com Canada
ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve - Yahoo Finance
ImmuCell Corporation (NASDAQ:ICCC) Q4 2025 Earnings Call Transcript - Insider Monkey
ImmuCell Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: ImmuCell’s Q4 2025 shows growth despite challenges - Investing.com
ImmuCell Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
ImmuCell Corporation Reports Improved Financial Results for 2025 with Increased Net Operating Income and Revenue Growth - Quiver Quantitative
ImmuCell (Nasdaq: ICCC) lifts 2025 EBITDA and narrows annual net loss - Stock Titan
Cattle health firm posts 2025 operating profit despite multi-million write-downs - Stock Titan
ImmuCell Corporation (NASDAQ:ICCC) Sees Significant Growth in Short Interest - MarketBeat
ImmuCell Corporation to Announce Unaudited Financial Results for Q4 and Year-End 2025 on March 4, 2026 - Quiver Quantitative
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above 200-Day Moving Average – What’s Next? - Defense World
Does ImmuCell Corporation have a sustainable dividendJuly 2025 WrapUp & Stepwise Entry/Exit Trade Alerts - mfd.ru
Why retail investors pile into ImmuCell Corporation stockJuly 2025 Big Picture & Low Risk Investment Opportunities - mfd.ru
Will ImmuCell Corporation benefit from AI trendsBear Alert & Weekly Momentum Stock Picks - mfd.ru
ImmuCell directors to step down at 2026 annual meeting, board changes expected By Investing.com - Investing.com South Africa
ImmuCell directors to step down at 2026 annual meeting, board changes expected - Investing.com
Two ImmuCell (ICCC) directors to step down after 2026 shareholder meeting - Stock Titan
ImmuCell announces new executive employment agreements and option grants By Investing.com - Investing.com South Africa
ImmuCell announces new executive employment agreements and option grants - Investing.com
Aug Intraday: Is ImmuCell Corporation forming a bullish divergence2025 Technical Patterns & Daily Volume Surge Trade Alerts - baoquankhu1.vn
ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
ImmuCell Corporation (NASDAQ:ICCC) Short Interest Update - MarketBeat
Those who invested in ImmuCell (NASDAQ:ICCC) a year ago are up 25% - Yahoo Finance
Earnings call transcript: ImmuCell Q4 2025 sees positive stock movement - Investing.com
Is ImmuCell Corporation stock resilient to inflationQuarterly Trade Summary & Precise Trade Entry Recommendations - Улправда
ImmuCell reports Q4 sales of $7.6 million, shifts focus to First Defense - Investing.com
Calf health company pauses one treatment to ramp a fast-growing product - Stock Titan
Macro Review: Is ImmuCell Corporation stock near bottom after declineJuly 2025 Pullbacks & Real-Time Buy Zone Alerts - Улправда
How rising interest rates impact ImmuCell Corporation stockCPI Data & Daily Market Momentum Tracking - ulpravda.ru
Will ImmuCell Corporation stock maintain dividend yieldJuly 2025 Short Interest & Trade Opportunity Analysis Reports - ulpravda.ru
ImmuCell Corporation Announces Investor Conference Call to Discuss Strategic Shift and Q4 2025 Sales Results - Quiver Quantitative
Cattle firm ImmuCell shifts focus to calf product, previews 2025 sales - Stock Titan
Head-To-Head Survey: Abbott Laboratories (NYSE:ABT) versus ImmuCell (NASDAQ:ICCC) - Defense World
The Christmas party is still ongoing in these stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - MSN
The Christmas Party Is Still Ongoing In These Stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - Asianet Newsable
ImmuCell Puts Re-Tain On Pause After FDA Letter - Benzinga
The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio - sharewise.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Top Stock Reports for AbbVie, Coca-Cola & Chevron - sharewise.com
Immucell Corp Stock (ICCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immucell Corp Stock (ICCC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| te Boekhorst Paul Francis Oliv | President and CEO |
Dec 03 '25 |
Buy |
5.02 |
6,077 |
30,536 |
9,785 |
| te Boekhorst Paul Francis Oliv | President and CEO |
Dec 02 '25 |
Buy |
4.87 |
3,708 |
18,053 |
3,708 |
| Tomsche David Scott | Director |
Nov 25 '25 |
Buy |
4.76 |
1,633 |
7,781 |
4,740 |
| Tomsche David Scott | Director |
Nov 25 '25 |
Buy |
4.76 |
1,633 |
7,773 |
52,720 |
| Basse Gloria F | Director |
Jun 11 '25 |
Option Exercise |
4.81 |
3,530 |
16,979 |
3,530 |
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):